cabozantinib (Cometriq®)

Reference No. 577

Publication date:

29/01/2015

Appraisal information

cabozantinib (Cometriq®) 20 mg capsule
cabozantinib (Cometriq®) 80 mg capsule

Company:	Swedish Orphan Biovitrum Ltd/TMC Pharma Services Ltd
BNF category:	Malignant disease and immunosupression
NMG meeting date:	19/11/2014
AWMSG meeting date:	17/12/2014

Submission Type:	Full Submission
Status:	Superseded
Advice No:	4014
Ratification by Welsh Government:	28/01/2015

Current Progress

Submission
received

NMG
meeting

AWMSG
meeting

Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA516) NICE GUIDANCE ISSUED FEBRUARY 2018 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

Final Appraisal Recommendation (FAR)

Download

Cabozantinib (Cometriq) 577 FAR

AWMSG Secretariat Appraisal Report (ASAR)

Download

Cabozantinib (Cometriq) 577 ASAR

Clinical Expert (CE) Summary

Download

Cabozantinib (Cometriq) 577 CE Summary